Quarterly report pursuant to Section 13 or 15(d)

Investments - Narrative (Details)

v3.20.2
Investments - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]          
Total assets of equity method investees $ 2,323,734   $ 2,323,734   $ 2,309,272
Total (liabilities) of equity method investees (735,391)   (735,391)   $ (694,513)
Net losses of equity method investees (33,703) $ 59,806 25,429 $ 140,568  
Market value 7,900   7,900    
Equity Method Investment, Nonconsolidated Investee or Group of Investees          
Schedule of Equity Method Investments [Line Items]          
Total assets of equity method investees 79,700   79,700    
Total (liabilities) of equity method investees $ (32,400)   (32,400)    
Net losses of equity method investees     $ 26,600    
Pharmsynthez          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 9.00%   9.00%    
Cocrystal          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 5.00%   5.00%    
Number of shares into which warrants may be converted (in shares) 33,000   33,000    
Non-Invasive Monitoring Systems, Inc.          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 1.00%   1.00%    
Neovasc          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 2.00%   2.00%    
InCellDx, Inc          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 29.00%   29.00%    
Number of shares into which warrants may be converted (in shares) 700,000   700,000    
BioCardia, Inc.          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 2.00%   2.00%    
Ownership percentage 2.00%   2.00%    
Number of shares into which warrants may be converted (in shares) 47,000   47,000    
Investment options, vested (in shares) 33,000   33,000    
Xenetic Biosciences, Inc.          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 3.00%   3.00%    
Number of shares into which warrants may be converted (in shares) 40,000   40,000    
Phio Pharmaceuticals          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage 0.02%   0.02%    
Number of shares into which warrants may be converted (in shares) 404   404    
VBI Vaccines Inc          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage 3.00%   3.00%    
ChromaDex          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage 0.10%   0.10%    
MabVax Therapeutics Holdings, Inc.          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage 1.00%   1.00%    
Eloxx Pharmaceuticals          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage 3.00%   3.00%    
Zebra          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage, equity method 29.00%   29.00%    
Series A Preferred Stock | Zebra          
Schedule of Equity Method Investments [Line Items]          
Investment owned (in shares) 1,260,000   1,260,000    
Restricted Stock | Zebra          
Schedule of Equity Method Investments [Line Items]          
Shares received as a gift (in shares)     900,000